The U.S. FDA grants market approval for Moderna’s mFLUSIVA (mRNA-1010) seasonal flu vaccine in adults 50+. Review Phase 3 trial data, efficacy, and rollout details.
Researchers at UPMC and Penn State have developed a new mRNA vaccine platform that is more scalable and adaptable, offering rapid protection against viruses like COVID-19 and H5N1.
The stepwise vaccination approach successfully activated and matured B cells toward producing broadly neutralizing antibodies, marking a major milestone in the pursuit of an effective HIV vaccine.
C. difficile vaccine protected against C. difficile first-time infections and relapsing infections in animal models by eliciting a strong immune response, facilitating the removal of pre-existing C. diff bacteria from the gut
mRNA vaccines are thought to be revolutionary. In addition to being utilized to combat the COVID-19 pandemic, they are also being considered for the treatment of several malignancies
Moderna’s new mRNA (messenger Ribonucleic Acid) flu shot completed the phase 3 trials with succeeding data. They are aiming to launch in early 2024. The flu vaccine – mRNA-1010 has produced an immune response against all four A and B strains – A/H1N1, A/H3N2, influenza B/Yamagata, and B/Victoria.
